Table 2 Treatment status at the termination of the double-blind Syst-Eur 1 trial
Active | ||
|---|---|---|
Placebo* | treatment* | |
Total number | 1691 | 1825 |
Still in double-blind follow-up | 1487 (88%) | 1718 (94%) |
No study drugs | 25 (1%) | 28 (2%) |
Nitrendipine/placebo only | 665 (39%) | 1065 (58%) |
Study medication other than | 797 (47%) | 625 (34%) |
nitrendipine | ||
Drugs taken† | ||
Nitrendipine/placebo | 1396 (83%) | 1514 (83%) |
Enalapril/placebo | 757 (45%) | 557 (31%) |
Hydrochlorothiazide/placebo | 399 (24%) | 220 (12%) |
Open-label antihypertensive | 20 (1%) | 13 (1%) |
drugs‡ | ||
Supervised open follow-up | 204 (12%) | 107 (6%) |
No antihypertensive drugs | 43 (3%) | 25 (1%) |
Open-label antihypertensive drugs | 142 (8%) | 74 (4%) |
Treatment unknown | 19 (1%) | 8 (0%) |